JP7642212B2 - 神経機能調節用組成物 - Google Patents

神経機能調節用組成物 Download PDF

Info

Publication number
JP7642212B2
JP7642212B2 JP2022501978A JP2022501978A JP7642212B2 JP 7642212 B2 JP7642212 B2 JP 7642212B2 JP 2022501978 A JP2022501978 A JP 2022501978A JP 2022501978 A JP2022501978 A JP 2022501978A JP 7642212 B2 JP7642212 B2 JP 7642212B2
Authority
JP
Japan
Prior art keywords
treatment
dementia
extract
improvement
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022501978A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2021167012A5 (https=
JPWO2021167012A1 (https=
Inventor
博子 礒田
一憲 佐々木
義信 新井
晴久 内田
健吾 岩田
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Tsukuba NUC
Nippo Co Ltd
Original Assignee
University of Tsukuba NUC
Nippo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Tsukuba NUC, Nippo Co Ltd filed Critical University of Tsukuba NUC
Publication of JPWO2021167012A1 publication Critical patent/JPWO2021167012A1/ja
Publication of JPWO2021167012A5 publication Critical patent/JPWO2021167012A5/ja
Application granted granted Critical
Publication of JP7642212B2 publication Critical patent/JP7642212B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Mycology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2022501978A 2020-02-18 2021-02-18 神経機能調節用組成物 Active JP7642212B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020025496 2020-02-18
JP2020025496 2020-02-18
PCT/JP2021/006166 WO2021167012A1 (ja) 2020-02-18 2021-02-18 神経機能調節用組成物

Publications (3)

Publication Number Publication Date
JPWO2021167012A1 JPWO2021167012A1 (https=) 2021-08-26
JPWO2021167012A5 JPWO2021167012A5 (https=) 2023-04-24
JP7642212B2 true JP7642212B2 (ja) 2025-03-10

Family

ID=77392155

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022501978A Active JP7642212B2 (ja) 2020-02-18 2021-02-18 神経機能調節用組成物

Country Status (2)

Country Link
JP (1) JP7642212B2 (https=)
WO (1) WO2021167012A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113694054A (zh) * 2021-09-29 2021-11-26 深圳市人民医院 一种化合物4-o-阿魏酰-5-o-咖啡酰奎宁酸甲酯在药物中的应用
JP7610209B2 (ja) * 2022-10-13 2025-01-08 国立大学法人 筑波大学 ミトコンドリア活性向上用組成物

Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004014159A1 (en) 2002-08-07 2004-02-19 Queen Bioactives Pty Ltd Method of lowering glycaemic index of foods
JP2005518381A (ja) 2001-12-19 2005-06-23 ザ キグリー コーポレーション 抹消神経・血管疾患の治療方法
JP2015528448A (ja) 2012-08-28 2015-09-28 ザ プロダクト メーカーズ （オーストラリア） プロプライエタリー リミテッド 抽出方法
JP2016531909A (ja) 2013-08-14 2016-10-13 テ ファ ファーマシューティカル カンパニー リミテッド フラボン−６−ｃ−グルコース誘導体を有効成分として含有する神経精神疾患治療又は予防用薬学的組成物
KR101766233B1 (ko) 2016-06-10 2017-08-08 한약진흥재단 루테올린 5-글루코사이드를 유효성분으로 포함하는 신경 질환의 예방 또는 치료용 조성물
JP2018039797A (ja) 2016-09-02 2018-03-15 花王株式会社 脳機能改善剤
WO2018199109A1 (ja) 2017-04-24 2018-11-01 学校法人産業医科大学 神経変性疾患治療剤
WO2018207791A1 (ja) 2017-05-12 2018-11-15 花王株式会社 Ａｒｃ発現促進剤
WO2018207790A1 (ja) 2017-05-12 2018-11-15 花王株式会社 アミロイドβ分解排出促進剤
CN108904488A (zh) 2018-04-24 2018-11-30 东北师范大学 一种化合物在降低蛋白聚积治疗老年痴呆方面的应用
CN109198628A (zh) 2018-10-10 2019-01-15 陶燃 一种治疗抑郁症及焦虑症的组合物及其用途
WO2019040989A1 (en) 2017-08-31 2019-03-07 The Product Makers (Australia) Pty Ltd IMPROVING THE TASTE OF CONSUMER PRODUCTS
CN110507645A (zh) 2019-09-24 2019-11-29 广东工业大学 木犀草素的应用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3793779B2 (ja) * 2000-11-27 2006-07-05 沖縄県 サトウキビポリフェノール含有物の製造方法
JP4199448B2 (ja) * 2001-10-30 2008-12-17 琉球セメント株式会社 サトウキビポリフェノール含有物を有効成分とする医薬剤並びにその用途
JP6289218B2 (ja) * 2014-03-31 2018-03-07 大阪瓦斯株式会社 ＰＰＡＲα活性組成物の活性化方法

Patent Citations (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005518381A (ja) 2001-12-19 2005-06-23 ザ キグリー コーポレーション 抹消神経・血管疾患の治療方法
WO2004014159A1 (en) 2002-08-07 2004-02-19 Queen Bioactives Pty Ltd Method of lowering glycaemic index of foods
JP2015528448A (ja) 2012-08-28 2015-09-28 ザ プロダクト メーカーズ （オーストラリア） プロプライエタリー リミテッド 抽出方法
JP2016531909A (ja) 2013-08-14 2016-10-13 テ ファ ファーマシューティカル カンパニー リミテッド フラボン−６−ｃ−グルコース誘導体を有効成分として含有する神経精神疾患治療又は予防用薬学的組成物
KR101766233B1 (ko) 2016-06-10 2017-08-08 한약진흥재단 루테올린 5-글루코사이드를 유효성분으로 포함하는 신경 질환의 예방 또는 치료용 조성물
JP2018039797A (ja) 2016-09-02 2018-03-15 花王株式会社 脳機能改善剤
WO2018199109A1 (ja) 2017-04-24 2018-11-01 学校法人産業医科大学 神経変性疾患治療剤
WO2018207791A1 (ja) 2017-05-12 2018-11-15 花王株式会社 Ａｒｃ発現促進剤
WO2018207790A1 (ja) 2017-05-12 2018-11-15 花王株式会社 アミロイドβ分解排出促進剤
WO2019040989A1 (en) 2017-08-31 2019-03-07 The Product Makers (Australia) Pty Ltd IMPROVING THE TASTE OF CONSUMER PRODUCTS
CN108904488A (zh) 2018-04-24 2018-11-30 东北师范大学 一种化合物在降低蛋白聚积治疗老年痴呆方面的应用
CN109198628A (zh) 2018-10-10 2019-01-15 陶燃 一种治疗抑郁症及焦虑症的组合物及其用途
CN110507645A (zh) 2019-09-24 2019-11-29 广东工业大学 木犀草素的应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
前田 剛希他，サトウキビ梢頭部の抗酸化能および抗酸化成分の同定，沖縄県農業研究センター研究報告，2010年，第4号，p.52-57

Also Published As

Publication number Publication date
WO2021167012A1 (ja) 2021-08-26
JPWO2021167012A1 (https=) 2021-08-26

Similar Documents

Publication Publication Date Title
Miodownik et al. Curcumin as add-on to antipsychotic treatment in patients with chronic schizophrenia: a randomized, double-blind, placebo-controlled study
Percival Grape consumption supports immunity in animals and humans
JP5503726B2 (ja) 学習・記憶障害および運動障害などを伴う中枢神経変性疾患を改善する乾燥植物組織および植物組織抽出物ならびにこれらを含有する医薬品および食品
Liu et al. Ellagic acid improves endogenous neural stem cells proliferation and neurorestoration through Wnt/β‐catenin signaling in vivo and in vitro
Choi et al. Valerian/Cascade mixture promotes sleep by increasing non-rapid eye movement (NREM) in rodent model
Kim et al. Sleep‐inducing effect of Passiflora incarnata L. extract by single and repeated oral administration in rodent animals
JP7642212B2 (ja) 神経機能調節用組成物
Li et al. Effect and mechanism of verbascoside on hypoxic memory injury in plateau
Dong et al. Kai-Xin-San, a traditional Chinese medicine formulation, exerts antidepressive and neuroprotective effects by promoting pCREB upstream pathways
Feng et al. Grape seed extract given three hours after injury suppresses lipid peroxidation and reduces hypoxic-ischemic brain injury in neonatal rats
Cruz-Martins et al. Paving Plant‐Food‐Derived Bioactives as Effective Therapeutic Agents in Autism Spectrum Disorder
JP7549933B2 (ja) 維持剤
JP6735224B2 (ja) アストロサイトのグルコース代謝活性化剤
Guo et al. FGF18 protects against 6-hydroxydopamine-induced nigrostriatal damage in a rat model of Parkinson’s disease
US11253566B2 (en) Composition for ameliorating, or treating depression and anxiety disorder comprising Fraxinus rhynchophylla extract as effective ingredient
Jiji et al. Neuroprotective effects of Clitoria ternatea L. against propionic acid-induced behavior and memory impairment in autistic rat model
US9801917B2 (en) Composition for improving blood sugar metabolism
CN107773580B (zh) 用于预防或治疗痴呆症或神经退行性疾病的生药组合物
JP7610209B2 (ja) ミトコンドリア活性向上用組成物
KR101470241B1 (ko) 우울증 예방 또는 치료용 약학적 조성물
Tang et al. Digirseophene A promotes recovery in injured developing cerebellum via AMPK/AKT/GSK3β pathway-mediated neural stem cell proliferation
Olawale et al. Comparative histoarchitectural and biochemical studies of the hippocampus in peroxisome proliferative activated receptor gamma agonist treated insulin resistant rats
KR102939527B1 (ko) 토맨토신을 유효성분으로 함유하는 우울증 및 불안증의 예방, 개선 또는 치료용 조성물
JP7584103B2 (ja) ブドウ果皮抽出物
US20240091293A1 (en) Immunity-enhancing composition containing syneilesis palmata extract as active ingredient

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230414

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230414

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240702

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241031

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250204

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250217

R150 Certificate of patent or registration of utility model

Ref document number: 7642212

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D04

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: R3D02